Omnicell (NASDAQ:OMCL) Lifted to “Buy” at StockNews.com

Omnicell (NASDAQ:OMCL) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

A number of other research firms have also commented on OMCL. Wells Fargo & Company lifted their price objective on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Bank of America boosted their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Finally, Benchmark reiterated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of “Moderate Buy” and an average price target of $39.50.

Omnicell Stock Down 1.9 %

NASDAQ:OMCL traded down $0.83 during midday trading on Thursday, hitting $42.12. 300,542 shares of the company were exchanged, compared to its average volume of 524,649. The company has a fifty day simple moving average of $42.91 and a 200 day simple moving average of $33.62. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $45.85. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $1.93 billion, a PE ratio of -91.57, a price-to-earnings-growth ratio of 46.63 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same period last year, the business earned $0.29 EPS. Omnicell’s revenue for the quarter was down 7.4% compared to the same quarter last year. As a group, equities analysts anticipate that Omnicell will post 0.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Vanguard Group Inc. lifted its holdings in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in Omnicell by 197.9% during the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock worth $3,642,000 after buying an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Omnicell by 61.3% in the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after buying an additional 228,093 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Omnicell in the first quarter valued at $684,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Omnicell during the 1st quarter valued at $718,000. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.